Bladder Cancer Treatment Market: By Cancer Type (Transitional Cell Bladder Cancer, Invasive Bladder Cancer, Superficial Bladder Cancer, Squamous Cell Bladder Cancer, Other Rare Types), By Drug Class (Chemotherapy And Immunotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) And By Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Bladder Cancer Treatment Market size was valued at 3.6 billion in 2022 and is expected to reach 4.8 billion by 2029, at a CAGR of 4.3% from 2023 to 2029. Bladder cancer is a disease in which malignant cells are formed in the tissues of the bladder. Symptoms of bladder cancer include blood in the urine, pain with urination, and low back pain. There are three types of bladder cancer that begin in the cells in the lining of the bladder. They are named transitional cell carcinoma, squamous cell carcinoma, and adenocarcinoma. As per the National Institute of Health, approximately 17,000 women and 45,000 men every year are diagnosed with bladder cancer in the U.S. only. The market for bladder cancer is rapidly increasing and it is anticipated to grow rapidly from 2016 to 2022 globally. According to The American Cancer Society, in 2017, estimated bladder cancers in the United States 79,030 new cases (about 60,490 in men and 18,540 in women) were diagnosed, and about 16,870 deaths from bladder cancer (about 12,240 in men and 4,630 in women). Bladder cancer accounts for about 5% of all new cancers in the US. It is the fourth most common cancer in men, but it is less common in women. In addition, the rise in awareness about bladder cancer and its available treatment options in the market, innovation in drug development, and subsequent technological advancements are expected to drive the market for bladder cancer treatment drugs. An increasing number of mergers and acquisitions, the rise in the number of collaborations and partnerships, new product launches, and growing awareness about the availability of bladder cancer treatment drugs are some of the latest trends that have been observed in the market.

Global Bladder Cancer Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4.3%

Largest Market

North America

Fastest Growing Market

Asia-Pacific
Bladder Cancer Treatment Market Dynamics

Increase in incidence rate of bladder cancer cases, technological advancements, drug innovations with regard to the treatment of bladder cancer, government initiatives, the rise in aging of the population, and advanced health care services are expected to drive the market for bladder cancer treatment drugs. In addition, the rise in awareness about bladder diseases, their available therapies in the market, and increase in health care expenditure are driving the global market for bladder cancer treatment drugs. However, the rise in a number of patent expirations, asymptomatic nature of the disease, and rise in the use of generic drugs are some of the major factors restraining the revenue growth of the global bladder cancer treatment drugs market over the forecast period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Bladder Cancer Treatment Market Segmentation

By Cancer Type
  • Transitional cell bladder cancer
  • Invasive bladder cancer
  • Superficial bladder cancer
  • Squamous cell bladder cancer
  • Other rare types
By Drug Class
  • Chemotherapy
    • Alkylating agents
    • Plant alkaloids
    • Taxanes
    • Anti-tumour Antibiotics
    • Anti-metabolites
    • Topoisomerase inhibitors
  • Immunotherapy
    • Tumor-targeting mAbs
    • DC-Based immunotherapy
    • Peptide- and DNA-based anticancer vaccines
    • Immune stimulatory cytokines
    • Immune modulatory mAbs
    • Immuno suppressive metabolism Inhibitors
    • Pattern recognition receptor Agonists
    • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Frequently Asked Questions

The bladder cancer treatment market key players are: AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Pfizer Inc.( U.S.), Sanofi (France)

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

  1. Executive summary
  2. Global Bladder Cancer Treatment Market Introduction
    • Global Bladder Cancer Treatment Market- Taxonomy
    • Global Bladder Cancer Treatment Market-Definitions
      • Drug Class
      • Cancer Type
  1. Global Bladder Cancer Treatment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Bladder Cancer Treatment Market Dynamics-Factors Impact Analysis
    • Global Bladder Cancer Treatment Market- Regulations
      • US
      • Europe
      • Japan
    • Global Bladder Cancer Treatment Market- Recent Product Launches
  2. Global Bladder Cancer Treatment Market Analysis, 2018 - 2022 and Forecast, 2023-2029
    • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Oppurtunity Analysis
  3. Global Bladder Cancer Treatment Market, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029
    • Chemotherapeutic Agents (Alkylating agents, Plant alkaloids, Taxanes, Anti-tumour Antibiotics, Anti-metabolites, and Topoisomerase inhibitors)
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Immunotherapy (Tumor-targeting mAbs, DC-Based immunotherapy, Peptide- and DNA-based anticancer vaccines, Immune stimulatory cytokines, Immun modulatory mAbs, and Others)
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Bladder Cancer Treatment Market Forecast, By Cancer Type, 2018 - 2022 and Forecast, 2023 - 2029
    • Transitional Cell Bladder Cancer
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Invasive Bladder Cancer
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Superficial Bladder Cancer
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Squamous Cell Bladder Cancer
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Other Rare Types
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Bladder Cancer Treatment Market Forecast, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029
    • Hospital Pharmacies
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Bladder Cancer Treatment Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029
    • North America
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Region, 2023-2029
  2. North America Bladder Cancer Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Drug Class Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Chemotherapy
        • Alkylating agents
        • Plant alkaloids
        • Taxanes
        • Anti-tumour Antibiotics
        • Anti-metabolites
        • Topoisomerase inhibitors
      • Immunotherapy
        • Tumor-targeting mAbs
        • DC-Based immunotherapy
        • Peptide- and DNA-based anticancer vaccines
        • Immune stimulatory cytokines
        • Immune modulatory mAbs
        • Immuno suppressive metabolism Inhibitors
        • Pattern recognition receptor Agonists
        • Others
      • Cancer Type Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
        • Transitional cell bladder cancer
        • Invasive bladder cancer
        • Superficial bladder cancer
        • Squamous cell bladder cancer
        • Other rare types
      • Distribution Channel Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
      • Country Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
        • US
        • Canada
      • North America Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2023-2029
      • North America Bladder Cancer Treatment Market Dynamics-Trends
  1. Europe Bladder Cancer Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Drug Class Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Chemotherapy
        • Alkylating agents
        • Plant alkaloids
        • Taxanes
        • Anti-tumour Antibiotics
        • Anti-metabolites
        • Topoisomerase inhibitors
      • Immunotherapy
        • Tumor-targeting mAbs
        • DC-Based immunotherapy
        • Peptide- and DNA-based anticancer vaccines
        • Immune stimulatory cytokines
        • Immune modulatory mAbs
        • Immuno suppressive metabolism Inhibitors
        • Pattern recognition receptor Agonists
        • Others
      • Cancer Type Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
        • Transitional cell bladder cancer
        • Invasive bladder cancer
        • Superficial bladder cancer
        • Squamous cell bladder cancer
        • Other rare types
      • Distribution Channel Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
      • Country Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
        • Germany
        • UK
        • France
        • Spain
        • Italy
        • Russia
        • Poland
        • Rest of Europe
      • Europe Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2023-2029
      • Europe Bladder Cancer Treatment Market Dynamics-Trends
  1. Asia-Pacific Bladder Cancer Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Drug Class Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Chemotherapy
        • Alkylating agents
        • Plant alkaloids
        • Taxanes
        • Anti-tumour Antibiotics
        • Anti-metabolites
        • Topoisomerase inhibitors
      • Immunotherapy
        • Tumor-targeting mAbs
        • DC-Based immunotherapy
        • Peptide- and DNA-based anticancer vaccines
        • Immune stimulatory cytokines
        • Immune modulatory mAbs
        • Immuno suppressive metabolism Inhibitors
        • Pattern recognition receptor Agonists
        • Others
      • Cancer Type Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
        • Transitional cell bladder cancer
        • Invasive bladder cancer
        • Superficial bladder cancer
        • Squamous cell bladder cancer
        • Other rare types
      • Distribution Channel Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
      • Country Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn),
  1. Y-o-Y Growth (%), and Market Share (%)
    • Japan
    • China
    • India
    • ASEAN
    • Australia & New Zealand
    • Rest of Asia-Pacific
  • Asia-Pacific Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2023-2029
  • Asia-Pacific Bladder Cancer Treatment Market Dynamics-Trends
  1. Latin America Bladder Cancer Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Drug Class Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Chemotherapy
        • Alkylating agents
        • Plant alkaloids
        • Taxanes
        • Anti-tumour Antibiotics
        • Anti-metabolites
        • Topoisomerase inhibitors
      • Immunotherapy
        • Tumor-targeting mAbs
        • DC-Based immunotherapy
        • Peptide- and DNA-based anticancer vaccines
        • Immune stimulatory cytokines
        • Immune modulatory mAbs
        • Immuno suppressive metabolism Inhibitors
        • Pattern recognition receptor Agonists
        • Others
      • Cancer Type Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
        • Transitional cell bladder cancer
        • Invasive bladder cancer
        • Superficial bladder cancer
        • Squamous cell bladder cancer
        • Other rare types
      • Distribution Channel Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
      • Country Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
        • Brazil
        • Mexico
        • Argentina
        • Venezuela
        • Rest of Latin America
      • Latin America Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2023-2029
      • Latin America Bladder Cancer Treatment Market Dynamics-Trends
  1. Middle East & Africa Bladder Cancer Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Drug Class Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Chemotherapy
        • Alkylating agents
        • Plant alkaloids
        • Taxanes
        • Anti-tumour Antibiotics
        • Anti-metabolites
        • Topoisomerase inhibitors
      • Immunotherapy
        • Tumor-targeting mAbs
        • DC-Based immunotherapy
        • Peptide- and DNA-based anticancer vaccines
        • Immune stimulatory cytokines
        • Immune modulatory mAbs
        • Immuno suppressive metabolism Inhibitors
        • Pattern recognition receptor Agonists
        • Others
      • Cancer Type Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
        • Transitional cell bladder cancer
        • Invasive bladder cancer
        • Superficial bladder cancer
        • Squamous cell bladder cancer
        • Other rare types
      • Distribution Channel Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
      • Country Analysis (2018-2022) and Forecast (2023-2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
        • Gulf Cooperation Council (GCC) Countries
        • Israel
        • South Africa
        • Rest of MEA
      • MEA Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2023-2029
      • MEA Bladder Cancer Treatment Market Dynamics-Trends
  1. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • AstraZeneca plc (U.K.)
      • Bristol-Myers Squibb (U.S.)
      • Celgene Corporation (U.S.)
      • Eli Lilly and Company (U.S.)
      • Hoffmann-La Roche (Switzerland)
      • GlaxoSmithKline plc (U.K.)
      • Novartis AG (Switzerland)
      • Pfizer Inc. (U.S.)
      • Sanofi (France)
  1. Research Methodology
  2. Key Assumptions and Acronyms
  • AstraZeneca plc (U.K.)
  • Bristol-Myers Squibb (U.S.)
  • Celgene Corporation (U.S.)
  • Eli Lilly and Company (U.S.)
  • F. Hoffmann-La Roche (Switzerland)
  • GlaxoSmithKline plc (U.K.)
  • Novartis AG (Switzerland)
  • Pfizer Inc.( U.S.)
  • Sanofi (France)

Adjacent Markets